Cassava sciences reports topline phase 3 refocus-alz data

Austin, texas, march 25, 2025 (globe newswire) -- cassava sciences, inc. (nasdaq: sava, “cassava”, the “company”), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for central nervous system disorders, including alzheimer's disease (ad) dementia and tuberous sclerosis complex (tsc)-related epilepsy, today shared topline results from the phase 3 refocus-alz study of simufilam in mild-to-moderate ad.
SAVA Ratings Summary
SAVA Quant Ranking